Evidence map›Paper›PMID 40093263›Full record

ArticlemedRxiv : the preprint server for health sciences2025

SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization.

Alex L Roederer, Yi Cao, Chia Jung Li, Eunice Lim, David H Canaday, Stefan Gravenstein, Alejandro B Balazs

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Alex L RoedererRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Yi CaoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Chia Jung LiRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Eunice LimRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
David H CanadayCase Western Reserve University School of Medicine, Cleveland, OH.
Stefan GravensteinCenter of Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island.
Alejandro B BalazsRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0002-1767-3944

Funding

Non-inferiority study of adjuvanted vs. high dose flu vaccine in residents of long term careR01AI129709 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI CANADAY, DAVID H, GRAVENSTEIN, STEFAN · 2018 to 2021
$4.7M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Eliminating the Immunogenicity of AAV Vectored HIV Antibody DeliveryR01AI174276 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Alejandro Benjamin Balazs · 2024 to 2026
$2.5M
AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIVR01AI174875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2023 to 2024
$1.6M
Development of Vectored ImmunoProphylaxis as a strategy against HIVK22AI102769 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2014 to 2015
$264k
NIAID NIH HHS K22 AI102769NIAID NIH HHS R01 AI129709NIAID NIH HHS R01 AI174276NIAID NIH HHS R01 AI174875NIDA NIH HHS DP2 DA040254
6 · The paper itself

Abstract

Studies have demonstrated that repeated mRNA vaccination enhances the breadth of neutralization against diverse SARS-CoV-2 variants. However, the development of antibodies capable of neutralizing across the Coronavirinae subfamily is poorly understood. In this study, we analyze serum samples to determine their neutralization breadth and potency and identify their antigenic targets. Using a cohort of older individuals and healthcare workers, we track correlates of broad neutralizing responses, including fusion peptide (FP) antibody elicitation. We find that although broadly neutralizing responses are often a result of RBD-specific antibodies, a rare subset of donors produce FP-specific broadly neutralizing responses. Interestingly, FP-specific antibodies are not observed in COVID-naive individuals irrespective of vaccination regimen, but rather, they occur following natural infection or vaccine breakthrough. This study highlights the epitope targets underpinning broadly neutralizing antibody responses to coronaviruses and suggests that existing vaccines are insufficient to promote the elicitation of FP-directed broadly neutralizing coronavirus antibodies.

Indexed as

broad neutralizationCOVID-19fusion peptideneutralizing antibodiesSARS-COV-2stem helix

Identifiers

PMID40093263
PMCPMC11908342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.